Literature DB >> 28629925

A 50% reduction in multiple live birth rate is associated with a 13% cost saving: a real-life retrospective cost analysis.

Karen Peeraer1, Thomas M D'Hooghe2, Cindy Vandoren3, Jeroen Trybou4, Carl Spiessens2, Sophie Debrock2, Diane De Neubourg5.   

Abstract

Belgian legislation limiting the number of embryos for transfer has been shown to result in a 50% reduction of the multiple live birth rate (MLBR) per cycle without having a negative impact on the cumulative delivery rate per patient within six cycles or 36 months. The objective of the current study was to evaluate the cost saving associated with a 50% reduction in MLBR. A retrospective cost analysis was performed of 213 couples, who became pregnant and had a live birth after one or more assisted reproductive technology treatment cycles, and their 254 children. The mean cost of a singleton (n = 172) and multiple (n = 41) birth was calculated based on individual hospital invoices. The cost analysis showed a significantly higher total cost (assisted reproductive technology treatment, pregnancy follow-up, delivery, child cost until the age of 2 years) for multiple births (both children: mean €43,397) than for singleton births (mean: €17,866) (Wilcoxon-Mann-Whitney P < 0.0001). A 50% reduction in MLBR resulted in a significant cost reduction related to hospital care of 13%.
Copyright © 2017 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Assisted reproduction; Cost analysis; Hospital costs; Live birth rate; Multiple pregnancy; Single embryo transfer

Mesh:

Year:  2017        PMID: 28629925     DOI: 10.1016/j.rbmo.2017.05.015

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  3 in total

Review 1.  Economic assessment of neonatal intensive care.

Authors:  Irene Guat Sim Cheah
Journal:  Transl Pediatr       Date:  2019-07

2.  The economic burden of infertility treatment and distribution of expenditures overtime in France: a self-controlled pre-post study.

Authors:  B Bourrion; H Panjo; P-L Bithorel; E de La Rochebrochard; M François; N Pelletier-Fleury
Journal:  BMC Health Serv Res       Date:  2022-04-15       Impact factor: 2.908

Review 3.  Growing body of evidence supports intrauterine insemination as first line treatment and rejects unfounded concerns about its efficacy, risks and cost effectiveness.

Authors:  Gulam Bahadur; Roy Homburg
Journal:  JBRA Assist Reprod       Date:  2019-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.